Emmanouil L. Pasparakis

Dr. Emmanouil L. Pasparakis

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2025 in Journal of Neurology and Experimental Neural Science
Verified
Journal Article
Open access
PDF file
EPEmmanouil L. Pasparakis
Emmanouil L. Pasparakis
EKErasmia I Koiliari
Erasmia I Koiliari
AVAntonios Vakis
Antonios Vakis
By Emmanouil L Pasparakis · 2025 · Read by 99 — Clinical recovery of symptoms after administration of long- acting treatment with injectable aripiprazole through recovery of inflammatory processes in parts of the brain and imaging results of brain CT scan of a patient of the field of Forensic Psychiatry with serious traumatic brain injury caused by a gunshot before and after undergoing neurosurgery in Journal of Neurology and Experimental Neural Science

8 August 2025 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
EKErasmia I. Koiliari
Erasmia I. Koiliari
IMIoannis Mouzas
Ioannis Mouzas
GAGeorgios Alevizopoulos
Georgios Alevizopoulos
OLOtto Lesch
Otto Lesch
HWHenriette Walter
Henriette Walter
EPEmmanouil L. Pasparakis
Emmanouil L. Pasparakis
Importance: Aripiprazole, a partial D2 receptor agonist, is proposed to enhance prefrontal cortex (PFC) dopamine function, improving working memory and GABA transmission, which supports social functioning. Long-acting injectable (LAI) antipsychotics are known to improve patient adherence, leading to enhanced long-term effects on behavioral outcomes.Objective: To evaluate whether aripiprazole LAI treatment improves general functioning, quality of life, and reduces hospitalizations in psychotic patients, both in community settings and within incarcerated populations.Design, settings, and participants: The study included 55 patients, with 34 from the community and 21 incarcerated at a prison in Southeastern Greece (Neapolis). The World Health Organization Quality of Life Brief Version (WHOQOL-BREF) and the Clinical Global Impression-Severity (CGI-S) scale were used to assess outcomes. Comparisons were made between pre-treatment and post-treatment periods, with a minimum follow-up of six months.Results: • Demographics: Community patients (70.6% male) included 44.1% with paranoid schizophrenia. Incarcerated patients (all male) had an F29.0 diagnosis, with 57.1% exhibiting Cluster B personality disorder and all reporting psychoactive substance use.• Hospitalizations: Community patients’ hospitalizations decreased from 1.4 to 0.1 over six months (p=0.001). Incarcerated patients’ hospitalizations dropped from 0.6 to 0.0 (p=0.066), with no significant intergroup difference (p=0.150).• CGI-S: Community patients’ scores improved from 6.0 to 3.9 (p<0.001). Incarcerated patients’ scores improved from 5.3 to 3.2 (p<0.001), with no significant difference between groups (p=0.814).• Quality of Life: Community patients’ scores rose from 0.5 to 3.0 (p<0.001), while incarcerated patients’ scores also increased significantly (p<0.001).Conclusions: This study of 34 community and 21 incarcerated patients revealed significant demographic and medical history differences. Both groups experienced reduced hospitalizations and improvements in CGI-S scores and quality of life following aripiprazole LAI administration. Community patients showed a greater reduction in hospitalizations, while clinical and quality-of-life improvements were comparable across groups.

14 August 2026 in Pediatric Reports
Verified
Journal Article
Open access
PDF file
EKErasmia I. Koiliari
Erasmia I. Koiliari
CTChristos Tsitsipanis
Christos Tsitsipanis
MKMarianna Evangelia Kapsetaki
Marianna Evangelia Kapsetaki
EPEmmanouil L. Pasparakis
Emmanouil L. Pasparakis
Background and Clinical Significance: This report investigates the complex intersection of macrostructural neuroprotection and cortical hyperexcitability during long-acting atypical antipsychotic maintenance. We present a novel clinical case demonstrating an apparent absence of detectable cerebellar vermis atrophy progression during long-acting injectable (LAI) aripiprazole maintenance, which temporally coincided with the emergence of a potential epileptogenic risk in an adolescent with bipolar disorder (BD) and cannabis use disorder. Beyond motor precision, the vermis modulates emotional-cognitive networks; deficits in these circuits impair impulse control, frequently driving comorbid substance use in youth. Case Presentation: A 16-year-old female with BD and cannabis use disorder presented with pronounced cerebellar and vermis atrophy on brain CT during an acute behavioral crisis. Following diagnostic reformulation, maintenance therapy was initiated via off-label monthly LAI aripiprazole (400 mg) alongside lithium. At 9-month follow-up, psychiatric relapses and cannabis use remitted completely. Repeat CT suggested macrostructural stability with zero apparent atrophy progression. However, during the 9th month, she abruptly developed daily generalized myoclonus. An awake electroencephalogram (EEG) revealed intense cortical hyperexcitability, documenting frequent interictal and ictal epileptiform discharges with generalized 3–4 Hz spike-wave complexes synchronized with the clinical myoclonus. Introduction of levetiracetam (500 mg BID) and cessation of adjunct methylphenidate led to complete clinical and neurophysiological remission. Conclusions: LAI aripiprazole may favorably influence the macrostructural trajectory of the cerebellum/vermis in adolescent BD, suggesting volume stabilization. However, clinicians must monitor for a drug-induced lowering of the seizure threshold, where macrostructural volume preservation coexists with microstructural electrical destabilization.

14 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
EKErasmia I. Koiliari
Erasmia I. Koiliari
GAGeorgios Ar Alevizopoulos
Georgios Ar Alevizopoulos
GDGeorgios I. Detorakis
Georgios I. Detorakis
AVAntonios Vakis
Antonios Vakis
EPEmmanouil L. Pasparakis
Emmanouil L. Pasparakis

Background: Managing comorbid psychotic disorders and cognitive impairments in community settings is clinically challenging. This study evaluates the real-world impact of Long-Acting Injectable (LAI) antipsychotics on psychiatric hospitalizations, clinical severity, and Quality of Life (QoL) in community-dwelling patients with intellectual or cognitive deficits. Methods: A symmetric, matched-pairs pre-post design was utilized to analyze a targeted cohort of 41 patients from the “DNAng” research project over a six-month observation window. The sample was stratified into two subgroups: a non-hospitalized cohort with primary intellectual disabilities (n = 22) and a previously hospitalized cohort characterized by neuroprogressive cognitive decline and dual diagnoses (n = 19). Main outcomes were tracked using the Clinical Global Impression-Severity (CGI-S) scale and the WHOQOL-BREF Global QoL item. Results: Baseline χ² testing revealed significant sociodemographic and diagnostic differences between the subcohorts (p < 0.05). Following LAI initiation, both groups demonstrated profound, statistically significant clinical improvements. In the non-hospitalized group, CGI-S decreased from 5.77 ± 0.86 to 3.09 ± 0.92 (p < 0.001; δ = 0.97) and QoL rose from 0.59 ± 0.50 to 3.13 ± 0.83 (p < 0.001; δ = -1.00). In the hospitalized group, total admissions plummeted from 2.10 ± 1.28 to 0.05 ± 0.22 (p = 0.0002; δ = 0.98), while involuntary prosecutor-ordered admissions collapsed to near-zero. CGI-S decreased to 3.78 ± 1.08 (p = 0.0003) and QoL reached 3.05 ± 0.84 (p = 0.0001). Conclusions: LAI antipsychotics provide a vital clinical safety net for cognitively vulnerable psychiatric populations, significantly reducing clinical severity, optimizing subjective well-being, and virtually eliminating traumatic and costly involuntary hospitalizations.


5 November 2026 in Psychiatry International
Verified
Journal Article
Open access
PDF file
EKErasmia I. Koiliari
Erasmia I. Koiliari
GAGeorgios Ar Alevizopoulos
Georgios Ar Alevizopoulos
GDGeorgios I. Detorakis
Georgios I. Detorakis
AVAntonios Vakis
Antonios Vakis
EPEmmanouil L. Pasparakis
Emmanouil L. Pasparakis
Background: Managing comorbid psychotic disorders and cognitive impairments in community settings is clinically challenging. This study evaluates the real-world outcomes associated with long-acting injectable (LAI) antipsychotics regarding psychiatric hospitalizations, clinical severity, and quality of life (QoL) in community-dwelling patients with intellectual or cognitive deficits. Methods: A retrospective, uncontrolled pre–post cohort study was conducted analyzing observational data from 41 patients enrolled in the “DNAng” research project over a six-month observation window. The sample was stratified into two subgroups: a non-hospitalized cohort with primary intellectual disabilities (n = 22) and a previously hospitalized cohort characterized by cognitive decline and dual diagnoses (n = 19). Main outcomes were tracked using the Clinical Global Impression-Severity (CGI-S) scale and the WHOQOL-BREF Global QoL item. Results: Baseline χ2 testing revealed significant sociodemographic and diagnostic differences between the subcohorts (p < 0.05). Following LAI initiation, both groups demonstrated statistically significant longitudinal changes. In the non-hospitalized group, CGI-S scores decreased from 5.77 ± 0.86 to 3.09 ± 0.92 (unadjusted p < 0.001; paired Cohen’s d = 3.01, 95% CI: [2.03, 3.99]) and QoL scores rose from 0.59 ± 0.50 to 3.13 ± 0.83 (unadjusted p < 0.001; paired Cohen’s d = −3.71, 95% CI: [−4.88, −2.53]). In the previously hospitalized group, total admissions decreased from a baseline median of 2.0 (IQR: 1.0–3.0) to a post-treatment median of 0.0 (IQR: 0.0–0.0) (Wilcoxon unadjusted p = 0.0002; paired Cohen’s d = 2.23, 95% CI: [1.39, 3.07]), accompanied by an observed decline in involuntary prosecutor-ordered admissions. Furthermore, CGI-S scores decreased to 3.78 ± 1.08 (unadjusted p = 0.0003; paired Cohen’s d = 2.22, 95% CI: [1.38, 3.06]), and QoL scores reached 3.05 ± 0.84 (unadjusted p = 0.0001; paired Cohen’s d = −3.64, 95% CI: [−4.88, −2.40]). Conclusions: In this retrospective evaluation, LAI antipsychotic administration was accompanied by observed reductions in clinical severity, concurrent improvements in subjective well-being scores, and lower rates of involuntary hospitalizations within this cognitively vulnerable population. These findings indicate an association between LAI formulations and clinical stability in community psychiatry, though controlled prospective studies remain essential to establish causal links.